Application of the international metastatic renal cell carcinoma database consortium and memorial sloan kettering cancer center risk models in patients with metastatic non-clear cell renal cell carcinoma

A multi-institutional retrospective study using the Korean metastatic renal cell carcinoma registry

Korean Renal Cell Carcinoma Study Group

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and the Memorial Sloan Kettering Cancer Center (MSKCC) risk models were developed predominantly with clear cell renal cell carcinoma (RCC). Accordingly, whether these two models could be applied to metastatic non-clear cell RCC (mNCCRCC) as well has not been well-known and was investigated herein. Materials and Methods From the Korean metastatic RCC registry, a total of 156 patients (8.1%) with mNCCRCC among the entire cohort of 1,922 patients were analyzed. Both models were applied to predict first-line progression-free survival (PFS), total PFS, and cancer-specific survival (CSS). Results The median first-line PFS, total PFS, and CSS were 5, 6, and 24 months, respectively. The IMDC risk model reliably discriminated three risk groups to predict survival: the median first-line PFS, total PFS, and CSS for the favorable, intermediate, and poor risk groups were 9, 5, and, 2 months (p=0.001); 14, 7, and 2 months (p < 0.001); and 41, 21, and 8 months (p < 0.001), all respectively. The MSKCC risk model also reliably differentiated three risk groups: 9, 5, and, 2 months (p=0.005); 10, 7, and 3 months (p=0.002); and 50, 21, and 8 months (p < 0.001), also all respectively. The concordance indices were 0.632 with the IMDC model and 0.643 with the MSKCC model for first-line PFS: 0.748 and 0.655 for CSS. Conclusion The current IMDC and MSKCC risk models reliably predict first-line PFS, total PFS, and CSS in mNCCRCC.

Original languageEnglish
Pages (from-to)758-768
Number of pages11
JournalCancer Research and Treatment
Volume51
Issue number2
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Renal Cell Carcinoma
Disease-Free Survival
Registries
Retrospective Studies
Databases
Neoplasms
Survival
Clear-cell metastatic renal cell carcinoma

Keywords

  • Criteria
  • Korean
  • Metastatic renal cell carcinoma
  • Non-clear cell
  • Prognosis
  • Validation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{0aa2196a270d4e1186a3234901f78469,
title = "Application of the international metastatic renal cell carcinoma database consortium and memorial sloan kettering cancer center risk models in patients with metastatic non-clear cell renal cell carcinoma: A multi-institutional retrospective study using the Korean metastatic renal cell carcinoma registry",
abstract = "Purpose The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and the Memorial Sloan Kettering Cancer Center (MSKCC) risk models were developed predominantly with clear cell renal cell carcinoma (RCC). Accordingly, whether these two models could be applied to metastatic non-clear cell RCC (mNCCRCC) as well has not been well-known and was investigated herein. Materials and Methods From the Korean metastatic RCC registry, a total of 156 patients (8.1{\%}) with mNCCRCC among the entire cohort of 1,922 patients were analyzed. Both models were applied to predict first-line progression-free survival (PFS), total PFS, and cancer-specific survival (CSS). Results The median first-line PFS, total PFS, and CSS were 5, 6, and 24 months, respectively. The IMDC risk model reliably discriminated three risk groups to predict survival: the median first-line PFS, total PFS, and CSS for the favorable, intermediate, and poor risk groups were 9, 5, and, 2 months (p=0.001); 14, 7, and 2 months (p < 0.001); and 41, 21, and 8 months (p < 0.001), all respectively. The MSKCC risk model also reliably differentiated three risk groups: 9, 5, and, 2 months (p=0.005); 10, 7, and 3 months (p=0.002); and 50, 21, and 8 months (p < 0.001), also all respectively. The concordance indices were 0.632 with the IMDC model and 0.643 with the MSKCC model for first-line PFS: 0.748 and 0.655 for CSS. Conclusion The current IMDC and MSKCC risk models reliably predict first-line PFS, total PFS, and CSS in mNCCRCC.",
keywords = "Criteria, Korean, Metastatic renal cell carcinoma, Non-clear cell, Prognosis, Validation",
author = "{Korean Renal Cell Carcinoma Study Group} and Kim, {Jung Kwon} and Kim, {Sung Han} and Song, {Mi Kyung} and Jungnam Joo and Seo, {Seong Il} and Cheol Kwak and Jeong, {Chang Wook} and Cheryn Song and Hwang, {Eu Chang} and Seo, {Ill Young} and Hakmin Lee and Hong, {Sung Hoo} and Park, {Jae Young} and Jinsoo Chung",
year = "2019",
month = "1",
day = "1",
doi = "10.4143/crt.2018.421",
language = "English",
volume = "51",
pages = "758--768",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Society for Thoracic and Cardiovascular Surgery",
number = "2",

}

TY - JOUR

T1 - Application of the international metastatic renal cell carcinoma database consortium and memorial sloan kettering cancer center risk models in patients with metastatic non-clear cell renal cell carcinoma

T2 - A multi-institutional retrospective study using the Korean metastatic renal cell carcinoma registry

AU - Korean Renal Cell Carcinoma Study Group

AU - Kim, Jung Kwon

AU - Kim, Sung Han

AU - Song, Mi Kyung

AU - Joo, Jungnam

AU - Seo, Seong Il

AU - Kwak, Cheol

AU - Jeong, Chang Wook

AU - Song, Cheryn

AU - Hwang, Eu Chang

AU - Seo, Ill Young

AU - Lee, Hakmin

AU - Hong, Sung Hoo

AU - Park, Jae Young

AU - Chung, Jinsoo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and the Memorial Sloan Kettering Cancer Center (MSKCC) risk models were developed predominantly with clear cell renal cell carcinoma (RCC). Accordingly, whether these two models could be applied to metastatic non-clear cell RCC (mNCCRCC) as well has not been well-known and was investigated herein. Materials and Methods From the Korean metastatic RCC registry, a total of 156 patients (8.1%) with mNCCRCC among the entire cohort of 1,922 patients were analyzed. Both models were applied to predict first-line progression-free survival (PFS), total PFS, and cancer-specific survival (CSS). Results The median first-line PFS, total PFS, and CSS were 5, 6, and 24 months, respectively. The IMDC risk model reliably discriminated three risk groups to predict survival: the median first-line PFS, total PFS, and CSS for the favorable, intermediate, and poor risk groups were 9, 5, and, 2 months (p=0.001); 14, 7, and 2 months (p < 0.001); and 41, 21, and 8 months (p < 0.001), all respectively. The MSKCC risk model also reliably differentiated three risk groups: 9, 5, and, 2 months (p=0.005); 10, 7, and 3 months (p=0.002); and 50, 21, and 8 months (p < 0.001), also all respectively. The concordance indices were 0.632 with the IMDC model and 0.643 with the MSKCC model for first-line PFS: 0.748 and 0.655 for CSS. Conclusion The current IMDC and MSKCC risk models reliably predict first-line PFS, total PFS, and CSS in mNCCRCC.

AB - Purpose The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and the Memorial Sloan Kettering Cancer Center (MSKCC) risk models were developed predominantly with clear cell renal cell carcinoma (RCC). Accordingly, whether these two models could be applied to metastatic non-clear cell RCC (mNCCRCC) as well has not been well-known and was investigated herein. Materials and Methods From the Korean metastatic RCC registry, a total of 156 patients (8.1%) with mNCCRCC among the entire cohort of 1,922 patients were analyzed. Both models were applied to predict first-line progression-free survival (PFS), total PFS, and cancer-specific survival (CSS). Results The median first-line PFS, total PFS, and CSS were 5, 6, and 24 months, respectively. The IMDC risk model reliably discriminated three risk groups to predict survival: the median first-line PFS, total PFS, and CSS for the favorable, intermediate, and poor risk groups were 9, 5, and, 2 months (p=0.001); 14, 7, and 2 months (p < 0.001); and 41, 21, and 8 months (p < 0.001), all respectively. The MSKCC risk model also reliably differentiated three risk groups: 9, 5, and, 2 months (p=0.005); 10, 7, and 3 months (p=0.002); and 50, 21, and 8 months (p < 0.001), also all respectively. The concordance indices were 0.632 with the IMDC model and 0.643 with the MSKCC model for first-line PFS: 0.748 and 0.655 for CSS. Conclusion The current IMDC and MSKCC risk models reliably predict first-line PFS, total PFS, and CSS in mNCCRCC.

KW - Criteria

KW - Korean

KW - Metastatic renal cell carcinoma

KW - Non-clear cell

KW - Prognosis

KW - Validation

UR - http://www.scopus.com/inward/record.url?scp=85064495289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064495289&partnerID=8YFLogxK

U2 - 10.4143/crt.2018.421

DO - 10.4143/crt.2018.421

M3 - Article

VL - 51

SP - 758

EP - 768

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 2

ER -